ASH 2022 | MagnetisMM-4: elranatamab in combination with other agents for patients with multiple myeloma
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some insights into the MagnetisMM-4 trial (NCT05090566), which is evaluating the safety and efficacy of elranatamab in combination with other anti-cancer agents in patients with multiple myeloma (MM). Dr Landgren also discusses two sub-studies in this trial: sub-study A, which is evaluating the safety and efficacy of elranatamab in combination with a gamma secretase inhibitor, and sub-study B, which is evaluating the safety and efficacy of elranatamab in combination with lenalidomide and dexamethasone. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials, Research Funding; Amgen: Research Funding; Merck: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials; Pfizer: Consultancy.
